Verrica Pharmaceuticals

Aaron Farberg, MD shares his perspective on buy and bill as a business strategy for dermatology practices and how it can improve patient care. "As dermatologists we constantly innovate and find new products to incorporate into our practice to improve the care we provide to our patients with skin diseases. Buy and bill can simply be an extension of the work you are already doing, and competent practice managers can incorporate these strategies based on your specific practice patterns and allow you to stay focused on your patients" https://hubs.li/Q02w_03-0

Happy National Dermatologist Day to all the skin experts helping their patients live better lives. At Verrica Pharmaceuticals, we deeply appreciate your dedication to skin health and innovation within dermatology. You play a vital role in addressing real patient needs, and your expertise is essential in developing new treatments and therapies.

Verrica Pharmaceuticals is proud to be a diamond level partner at the 2024 Association of Military Dermatologists Annual Meeting. Thank you all for your service and the opportunity to learn more from the military dermatology community. 

Learn more about our Sales Team Expansion opportunities at www.verrica.com/careers

Putting the finishing touches in place for #FallClinical23. Join us Friday and Saturday in the Bandol room for a hands on demonstration with the YCANTH applicator. Join us today at 11:30 for a product theater hosted by Dr. Adelaide Hebert in the Meursault 2 room.

“Nothing’s easy, but it’s all about perseverance, commitment and steadfast leadership.” Celebrating five years #NasdaqListed, Verrica Pharmaceuticals President & CEO Ted White sits down with Nasdaq to reflect on the past five years of being a public company, and what $VRCA is looking to achieve in the years to come.

Join us on October 11th at 11am ET for a virtual KOL Event with Verrica Pharmaceuticals (#VRCA), featuring Mark D. Kaufmann MD, Michael Cameron, MD FAAD, and Mercedes Gonzalez, MD discussing the recent approval of YCANTH™ (VP-102) as the only product approved by the FDA to treat #molluscum in adult and pediatric patients two years of age and older. Register here: https://lnkd.in/eM7T5qHN

Verrica Pharmaceuticals is ringing in 5️⃣ years as a #NasdaqListed company. 🛎️ $VRCA is a dermatology therapeutics company developing novel treatments that provide meaningful benefits for people living with skin diseases. We look forward to supporting their growth and progress as they continue to innovate dermatological treatments.

Day 2 of the Verrica National Sales Meeting was an exciting one! We had the opportunity to listen to leading KOLs as they shared their thoughts on how YCANTH can help their patients.

IMPORTANT NEWS: The FDA has issued six warning letters to retail giants including Amazon and Walmart for selling unapproved products online for the treatment of molluscum contagiosum. “[The] FDA is concerned that people are forgoing or delaying proper diagnosis and treatment of a potentially serious, undiagnosed health condition by purchasing and using an unapproved drug product claiming to treat molluscum.” The FDA also issued warning letters to four companies making the unapproved molluscum products. https://lnkd.in/eGU8kmXA